Together, the present data revealed YLZD could ameliorate HFD-induced NAFLD in rats by the modulation of SIRT1/Nrf2 signaling pathway and gut microbiota. This evidence concerns the gene SIRT1 and metabolic dysfunction-associated steatotic liver disease.